Formats
  1. Journal Article (66747)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Precision targeting of MYD88 mutant DLBCL using the novel combination of irakimids and BCL2 inhibition
    Meeting Abstract

    Grilo, A. M.; Klaus, C.; McDonald, A.; Gollob, J.; Weiss, M.; O'Connor, O. A.; Salles, G.; Chaudhuri, J.; Lue, J. K.
    Blood (2022)

    Fulltext@MSK | Save
  • Cohesin dependency in NPM1(c/+) and FLT3-ITD mutant hematopoietic stem and progenitor cells
    Meeting Abstract

    Xu, J. J.; Alija, B.; Braunstein, S.; Pantazi, J.; Sudunagunta, V. S.; Bowman, R. L.; Viny, A. D.
    Blood (2022)

    Fulltext@MSK | Save
  • Trends in collection and utilization of autologous hematopoietic stem cells (APBHC) intended for transplant in patients with multiple myeloma
    Meeting Abstract

    Samuel, N.; Laufer, L.; Tanaguchi, R.; Rosiene, J.; Palesi, C.; Elkind, R.; Mantzaris, I.; Shastri, A.; Kornblum, N.; Sica, R. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2/3, randomized, double blind, placebo-controlled, multicenter study of NKTR-255 vs placebo following CD-19 directed CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma
    Meeting Abstract

    Perales, M. A.; Ahmed, S.; Dahiya, S.; Riedell, P. A.; McGuirk, J. P.; Oluwole, O. O.; Chaudhry, S. A.; Lee, Z.; Dai, S.; Dixit, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Updated efficacy and safety of tabelecleucel in patients with Epstein-Barr virus-positive (EBV(+)) leiomyosarcomas (LMS)
    Meeting Abstract

    Jimenez-Kurlander, L. S.; Behr, G.; Bunin, N. J.; Doubrovina, E.; Dinavahi, R.; Gamelin, L.; Ghobadi, A.; Mascarenhas, L.; Nikiforow, S.; O'Reilly, R. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Antigen directed therapy pre-transplant confers superior post-transplant survival outcome compared to conventional chemotherapy in pediatric patients with relapsed and refractory B-ALL
    Meeting Abstract

    Stiefel, J.; Flower, A. M.; Botwinick, M.; Ford, M.; Foti, A.; Gandhi, M.; Slovin, J.; Smilow, E.; Bowers, A.; Karpel, H.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the phase 3 MAIA study
    Meeting Abstract

    Moreau, P.; Facon, T.; Usmani, S.; Bahlis, N. J.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Meeting Abstract

    Nooka, A. K.; Cohen, A.; Lee, H. C.; Badros, A. Z.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (Pts): Final analysis of griffin among clinically relevant subgroups
    Meeting Abstract

    Chari, A.; Kaufman, J. L.; Laubach, J. P.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial results of dose escalation of ISB 1342, a novel CD3xCD38 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Mohan, S. R.; Chase, C. C.; Berdeja, J. G.; Karlin, L.; Belhadj, K.; Perrot, A.; Moreau, P.; Touzeau, C.; Chalopin, T.; Lesokhin, A. M.; more...
    Blood (2022)

    Fulltext@MSK | Save